Skip to main content

Table 3 Proinflammatory protein mRNAs expression in brainstem and cerebellum of MOG35-55 immunized mice treated with Veh or PEALut

From: A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis

  Brainstem Cerebellum
PID PID
7 14 21 7 14 21
TNF-α/GADPH Veh 1.0 ± 0.1 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.2
MOG/Veh 2.5 ± 0.3 106.4 ± 33.3°°° 21.6 ± 6.5 1.6 ± 0.1 71.7 ± 19.7°°° 32.2 ± 14.1
MOG/PEALut 2.4 ± 0.4 52.6 ± 21.9* 15.9 ± 4.5 2.0 ± 0.2 31.9 ± 11.4** 16.5 ± 4.6
IL1-β/GADPH Veh 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.5 1.0 ± 0.5
MOG/Veh 2.4 ± 0.6 330.2 ± 77.8°°° 31.5 ± 6.9 2.1 ± 0.3 123.0 ± 78.6° 21.8 ± 8.8
MOG/PEALut 4.7 ± 2.0 174.7 ± 65.8** 23.7 ± 6.5 4.0 ± 0.8 18.8 ± 12.2* 14.8 ± 6.8
INFγ/GADPH Veh 1.0 ± 0.2 1.0 ± 0.5 1.0 ± 0.4 1.0 ± 0.2 1.0 ± 0.4 1.0 ± 0.2
MOG/Veh 1.0 ± 0.3 115.2 ± 0.5°°° 19.2 ± 4.7 1.7 ± 0.5 37.8 ± 15.7°° 27.8 ± 8.1
MOG/PEALut 1.4 ± 0.3 35.7 ± 17.2** 19.3 ± 7.7 1.0 ± 0.1 6.9 ± 1.8* 22.5 ± 10.4
NLRP3/GADPH Veh 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
MOG/Veh 0.7 ± 0.0 11.2 ± 1.4°°° 3.3 ± 0.6 0.7 ± 0.1 7.2 ± 2.0°°° 4.4 ± 0.8°
MOG/PEALut 1.0 ± 0.2 6.9 ± 2.2** 2.2 ± 0.6 0.9 ± 0.1 2.9 ± 0.6** 2.9 ± 0.6
  1. Mice were treated with Veh, MOG/Veh, or MOG/PEALut for 7, 14, and 21 days. Veh or PEALut treatments started at 11 PID. TNF-α, IL-1β, INFγ, and NLRP3 mRNAs values are reported as mean ± SEM. Data are shown as relative expression of Veh-treated values normalized to 1. n = 6 mice for each group. °p < 0.05, °°p < 0.01, and °°°p < 0.001 compared with the Veh-treated group. *p < 0.05 and **p < 0.01 compared with the MOG/Veh